Investigational drug · Phase 3
nivolumab and relatlimab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
98
Any phase or sponsor naming "nivolumab and relatlimab"
First trial start
2025
Aug 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "nivolumab and relatlimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma (Skin Cancer)
- Melanoma Stage IIIB-IV
- Cutaneous Melanoma
- Unresectable Melanoma
Approved drugs for the same conditions: Melanoma · Oncology · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "nivolumab and relatlimab" as an intervention, largest first.
Groupe Hospitalier Pitie-SalpetriereAcademic, hospital or other
NCT05934214 · 141,630 participants · Start Jan 1, 2023 · Primary completion Dec 31, 2023
Drug: Immune checkpoint inhibitor · For: Cancer; Immune-related Adverse Event; Immune Checkpoint Inhibitor-Related Myocarditis
Sites: Paris, France · 2 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- Pan Tumor Rollover StudyRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03899155 · 1,500 participants (planned) · Start Aug 9, 2019 · Primary completion Aug 25, 2029
Drug: Nivolumab; Ipilimumab and 17 more · For: Cancer
Sites: Huntsville, Alabama; Tucson, Arizona; Lynwood, California · 410 sites in all
- An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT01968109 · 1,482 participants · Start Nov 5, 2013 · Primary completion May 22, 2024
Drug: Relatlimab; Nivolumab and 1 more · For: Neoplasms by Site
Sites: La Jolla, California; Aurora, Colorado; Tampa, Florida · 54 sites in all
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsPivotal-lookingRecruiting
ExelixisIndustry
NCT05176483 · 1,394 participants (planned) · Start Dec 14, 2021 · Primary completion Jan 31, 2027
Drug: Zanzalintinib; Nivolumab and 5 more · For: Renal Cell Carcinoma (RCC); Metastatic Castration-Resistant Prostate Cancer (mCRPC); Urothelial Carcinoma (UC) and 8 more
Sites: Phoenix, Arizona; Tucson, Arizona; Palo Alto, California · 122 sites in all
- A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaPivotal-lookingTerminated
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05002569 · 1,093 participants · Start Oct 19, 2021 · Primary completion Dec 16, 2024
Drug: Nivolumab; Nivolumab + Relatlimab Fixed Dose Combination · For: Melanoma
Sites: Birmingham, Alabama; Springdale, Arkansas; Los Angeles, California · 184 sites in all
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06561386 · 1,000 participants (planned) · Start Oct 7, 2024 · Primary completion Jul 30, 2030
Drug: Nivolumab; Relatlimab and 4 more · For: Non-small Cell Lung Cancer
Sites: Mobile, Alabama; Tucson, Arizona; Los Angeles, California · 330 sites in all
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05987241 · 992 participants (planned) · Start Feb 2, 2024 · Primary completion Sep 2, 2030
Drug: Nivolumab; Relatlimab · For: Muscle Invasive Bladder Urothelial Carcinoma; Muscle Invasive Renal Pelvis Urothelial Carcinoma; Muscle Invasive Ureter Urothelial Carcinoma and 4 more
Sites: Phoenix, Arizona; Tucson, Arizona; Fayetteville, Arkansas · 505 sites in all
- A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced MelanomaPivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03470922 · 714 participants · Start Apr 11, 2018 · Primary completion Jan 25, 2021
Drug: Relatlimab; Nivolumab · For: Melanoma
Sites: Tucson, Arizona; Los Angeles, California; San Luis Obispo, California · 127 sites in all
- IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)Pivotal-lookingRecruiting
Immunocore LtdIndustry
NCT06112314 · 680 participants (planned) · Start Jun 5, 2024 · Primary completion Oct 16, 2027
Drug: Brenetafusp; Nivolumab and 1 more · For: Advanced Melanoma
Sites: Tucson, Arizona; La Jolla, California; Los Angeles, California · 211 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Systemic treatment strategies for BRAF wild-type metastatic unresectable melanoma: a network meta-analysis.
Zhou Y, He Y, Tan X · Front Oncol 2026
- Predicting Targeted and Immunotherapeutic Response Outcomes in Melanoma With Single-Cell Raman Spectroscopy and Artificial Intelligence.
Chang K, Serasanambati M, Ogunlade B, et al. · JCO Precis Oncol 2026
- Acral lentiginous melanoma metastases to the vitreous masquerading as uveitis: A case report.
Chahal R, Ahuja P, Al-Zangana R, et al. · Am J Ophthalmol Case Rep 2026
- Complete Response to Nivolumab-Relatlimab Following Progression of Invasive Sinonasal Mucosal Melanoma on First-Line Nivolumab-Ipilimumab: A Case Report.
Patel R, Post-Zwicker L, Kaur V · Cancer Rep (Hoboken) 2026
- Predicting targeted- and immunotherapeutic response outcomes in melanoma with single-cell Raman spectroscopy and AI.
Chang K, Serasanambati M, Ogunlade B, et al. · bioRxiv 2026
- Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression.
Khatri VM, Aboujaoude M, Karapetyan L, et al. · J Neurooncol 2026
Also in development for Melanoma (Skin Cancer)
- ipilimumab and nivolumabPhase 31 trial
Linnaeus Therapeutics, Inc. · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma
- LNS8801Phase 31 trial
Linnaeus Therapeutics, Inc. · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.